Improving spinal fusion by optimizing scaffold and surface engineering is a topic of interest for both surgeons and researchers. Concerns regarding patient safety with off-label use of bone morphogenetic protein (BMP) have increased, and patients are choosing minimally invasive spine surgery to lessen morbidity by avoiding harvest of bone graft. These trends may be driving studies on how surgeons can avoid issues associated with biologics (e.g., cost, morbidity), while achieving efficacious and safe bone fusion.
|Original language||English (US)|
|State||Published - Jan 1 2016|
- Stem cells
- Tissue engineering
ASJC Scopus subject areas
- Orthopedics and Sports Medicine
- Clinical Neurology